
IDEXX Hits $1.1 Billion Net Income Driven by 79% Recurring Revenue
IDEXX Laboratories, Inc.Description
What this story covers
IDEXX Laboratories demonstrated financial resilience in 2025, leveraging AI-powered diagnostic innovations and a 79% recurring revenue model to achieve $1.1 billion in net income, successfully offsetting a 2% decline in U.S. veterinary clinical visits.
Story snapshot
CompanyIDEXX Laboratories, Inc.
TickerIDXX
VariantStandard detailed
Duration11:14
Filing type10-K
PeriodAnnual 2025
IndustryHealthcare & Pharmaceuticals
Accession0000874716-26-000038
Sources1
Full Story Script
Content not available for this story.